Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Your Article Summary
See Latest ArticlesCost-Effectiveness Analysis of Raltegravir in Treatment-Experienced HIV Type 1-Infected Patients in Spain
AIDS Research and Human Retroviruses, 06/26/09
Chaudhary MA et al. - Lower ICERs were observed with lower discount rates for costs and benefits, lower raltegravir price, and shorter treatment duration. ICER was also sensitive to analytical time horizon and alternative sources of QoL scores. In treatment-experienced Spanish patients, raltegravir was projected to provide survival benefits and be cost effective.
Related Articles
Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways
Journal of Virology, 10/26/09
Relevance Score: 87%
Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life
Journal of Clinical Virology, 10/13/09
Relevance Score: 84%
Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure
Antimicrobial Agents and Chemotherapy, 10/09/09
Relevance Score: 80%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Milnacipran: Beyond a Role of Antidepressant
Clinical Neuropharmacology, 12/14/09
Thiazolidinediones and the liver in humans
Current Opinion in Lipidology, 12/14/09
Effect of Obesity on Platelet Reactivity and Response to Low-Dose Aspirin
Preventive Cardiology, 12/14/09
Sponsor
Article Search
Sponsor
Sponsor